We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
Read MoreHide Full Article
Shire plc announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.
The candidate was added to Shire’s portfolio through the acquisition of erstwhile Baxalta Inc. in 2016.
We note that the FDA's Fast Track process facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Shire plans to initiate a randomized, open-label, 2-period crossover study with a single arm continuation phase III trial to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency. The trial will be conducted in the U.S., Europe, and Japan.
Shire’s shares have outperformed the Zacks classified Medical-Drugs industry. The stock gained 3.7% in the last three months better than the industry’s gain of 2.2%.
We note that Shire has a dominant position in the rare diseases market, which is growing faster than the broader biopharmaceutical market. Strong performance of Vyvanse, Lialda and Firazyr should continue to drive its top line in the upcoming quarters. The approval of Xiidra has boosted the company’s ophthalmology space.
Shire continues to broaden its product portfolio through acquisitions and partnerships. The acquisition of Baxalta added key products to Shire's hematology, oncology and immunology franchises. These include Oncaspar, a marketed biologic treatment for acute lymphocytic leukemia along with pacritinib, an experimental oral kinase inhibitor for the treatment of myelofibrosis.
Zacks Rank & Stock to Consider
Shire currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector include Heska Corporation , Anthera Pharmaceuticals, Inc. (ANTH - Free Report) and Retrophin, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018 over the last 30 days. The company posted a positive earnings surprise in all the four trailing quarters with an average beat of 291.54%. Its share price increased 34.2% year to date.
Anthera’s loss estimates narrowed from $1.49 to $1.17 for 2017 over the last 60 days.
Retrophin’s loss estimates narrowed from 85 cents 72 cents for 2017 and from 67 cents to 53 cents for 2018 over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
Shire plc announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.
The candidate was added to Shire’s portfolio through the acquisition of erstwhile Baxalta Inc. in 2016.
We note that the FDA's Fast Track process facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Shire plans to initiate a randomized, open-label, 2-period crossover study with a single arm continuation phase III trial to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency. The trial will be conducted in the U.S., Europe, and Japan.
Shire’s shares have outperformed the Zacks classified Medical-Drugs industry. The stock gained 3.7% in the last three months better than the industry’s gain of 2.2%.
We note that Shire has a dominant position in the rare diseases market, which is growing faster than the broader biopharmaceutical market. Strong performance of Vyvanse, Lialda and Firazyr should continue to drive its top line in the upcoming quarters. The approval of Xiidra has boosted the company’s ophthalmology space.
Shire continues to broaden its product portfolio through acquisitions and partnerships. The acquisition of Baxalta added key products to Shire's hematology, oncology and immunology franchises. These include Oncaspar, a marketed biologic treatment for acute lymphocytic leukemia along with pacritinib, an experimental oral kinase inhibitor for the treatment of myelofibrosis.
Zacks Rank & Stock to Consider
Shire currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector include Heska Corporation , Anthera Pharmaceuticals, Inc. (ANTH - Free Report) and Retrophin, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018 over the last 30 days. The company posted a positive earnings surprise in all the four trailing quarters with an average beat of 291.54%. Its share price increased 34.2% year to date.
Anthera’s loss estimates narrowed from $1.49 to $1.17 for 2017 over the last 60 days.
Retrophin’s loss estimates narrowed from 85 cents 72 cents for 2017 and from 67 cents to 53 cents for 2018 over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>